PACIRA BIOSCIENCES, INC. Business Acquisition, Pro Forma Earnings Per Share, Diluted
PACIRA BIOSCIENCES, INC. (PCRX) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$0.08 per share for the 3-month period ending 2021-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2022-08-03
- PACIRA BIOSCIENCES, INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2021-06-30 was -$0.08.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month |
|---|---|
| 2021-06-30 | -$0.08 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |